Education
About Us
Working with TipRanks
Follow Us
Scott Dunseth Myers Insider Profile
4 Followers
Scott Dunseth Myers, President & CEO, Director at Cascadian Therapeutics, holds 260.19K shares in Zentalis Pharmaceuticals (Ticker: ZNTL), holds 25.45K shares in Dynavax (Ticker: DVAX), holds 0.00 shares in Harpoon Therapeutics (Ticker: HARP).
Scott Dunseth Myers Cascadian Therapeutics (CASC)President & CEO, Director
Cascadian Therapeutics (CASC)
President & CEO, Director
Ranked #5,367 out of 100,956 Corporate Insiders
Profitable Transactions
3 out of 7 Profitable Transactions
Average Return
+47.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Scott Dunseth Myers holds in companies
Most Profitable Insider Trade
Stock:
Cascadian Therapeutics
(CASC)
(CASC)
Rating:Informative Buy
Date:Mar 21, 2017 - Mar 21, 2018
Return:+175.10%
The most profitable trade made by Scott Dunseth Myers
Scott Dunseth Myers's Trading History
Cascadian Therapeutics
Mar 13, 2018
―
Uninformative Sell
―
$0.00
Harpoon Therapeutics
Mar 11, 2024
―
Uninformative Sell
―
$0.00
Cartesian Therapeutics
Dec 26, 2019
Director
Uninformative Buy
57.54K
$1.49M
Amag Pharmaceuticals
―
―
―
―
Trillium Therapeutics
―
―
―
―
Dynavax
May 28, 2024
Director
Uninformative Buy
―
$366.42K
Viridian Therapeutics
Apr 12, 2023
CEO, Director
Informative Buy
101.44K
$4.14M
Zentalis Pharmaceuticals
Nov 13, 2024
Director
Uninformative Buy
―
$473.55K
List of latest transactions for each holding click on a transaction to see Scott Dunseth Myers's performance on stock
You May Also Like
Scott Dunseth Myers insider profile FAQ
What is the percentage of profitable transactions made by Scott Dunseth Myers?
The percentage of profitable transactions made by Scott Dunseth Myers is 43%.
What is the average return per transaction made by Scott Dunseth Myers?
The average return per transaction made by Scott Dunseth Myers is 47.30%.
What stocks does Scott Dunseth Myers hold?
Scott Dunseth Myers holds: CASC, HARP, RNAC, AMAG, TRIL, DVAX, VRDN, ZNTL stocks.
What was Scott Dunseth Myers’s latest transaction?
Scott Dunseth Myers latest transaction was an Uninformative Buy of ―.
What was Scott Dunseth Myers's most profitable transaction?
Scott Dunseth Myers’s most profitable transaction was an Informative Buy of CASC stock on March 21, 2017. The return on the trade was 175.10%.
What is Scott Dunseth Myers's role in Cascadian Therapeutics?
Scott Dunseth Myers's role in Cascadian Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.